Thymalin: a thymic peptide with immunomodulatory and anti-aging properties

Summary

This review compiled the clinical and preclinical evidence for thymosin alpha-1 (Ta1), a 28-amino acid peptide originally isolated from thymic tissue, as an immunomodulatory agent. Ta1 has been approved in over 35 countries for the treatment of hepatitis B and C and as an immune adjuvant, with extensive clinical data supporting its role in enhancing both innate and adaptive immunity.

Key Findings

• Thymosin alpha-1 activates dendritic cells via TLR9 signaling, enhancing antigen presentation and bridging innate and adaptive immune responses
• Clinical studies demonstrated that Ta1 improves immune reconstitution, increases CD4+/CD8+ T-cell ratios, and enhances NK cell cytotoxicity in immunocompromised patients
• Ta1 has been used as a vaccine adjuvant to enhance immune responses in elderly and immunocompromised populations with an excellent safety profile across over 4,400 patients in clinical trials